 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 September 1995 | Volume 123 Issue 6 | Pages 401-408
Objective: To test whether slow-release sodium fluoride inhibits spinal fractures and is safe to use.
Design: Placebo-controlled randomized trial.
Interventions: Slow-release sodium fluoride, 25 mg twice daily, in four 14-month cycles (12 months receiving sodium fluoride followed by 2 months not receiving it) compared with placebo. Calcium citrate, 400 mg calcium twice daily, continuously in both groups.
Patients: 48 of 54 patients who received sodium fluoride and 51 of 56 patients who received placebo completed at least 1 year of the study. All patients had postmenopausal osteoporosis.
Results: Compared with the placebo group, the fluoride group had a lower individual vertebral fracture rate (0.064 ± 0.182 per patient-year compared with 0.205 ± 0.297 per patient-year; P = 0.002), a higher unadjusted fracture-free rate (85.4% compared with 56.9%; P = 0.001), and a greater survival estimate (relative risk, 0.3 [95% CI, 0.12 to 0.76]) for new fractures. The recurrent spinal fracture rate did not differ between the two groups. The fluoride group had a substantial increase in L2-L4 bone mass of 4% to 5% per year for 4 years, a mean increase in femoral neck bone density of 2.38% ± 3.33% per year, and no change in radial shaft bone density. The frequency with which minor side effects and appendicular fractures occurred was similar in the two groups; no patients developed microfractures or gastric ulcers.
Conclusion: Slow-release sodium fluoride and calcium citrate administered for 4 years inhibits new vertebral fractures (but not recurrent fractures), augments spinal and femoral neck bone mass, and is safe to use.
Author and Article Information
From the University of Texas Southwestern Medical Center, Dallas, Texas, and the Scott and White Clinic, Temple, Texas.
ARTICLE
Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial
Note: Slow Fluoride is an investigational drug study under the Food and Drug Administration's investigational new drug application number 20 612. The University of Texas Southwestern Medical Center, the sponsor of the investigational new drug application, holds all rights to this drug. The Mission Pharmacal Company, the manufacturer of Slow Fluoride, has provided the drug free of charge for this trial but has not offered other research support. Dr. Pak is the principal investigator of the investigational new drug application. None of the investigators has equity in, receives direct compensation from, or serves on the Board of the Mission Pharmacal Company.
Grant Support: In part by grants R01-AR-16061 and M01-RR00633 from the United States Public Health Service, and by institutional funds.
Requests for Reprints: Charles Y.C. Pak, MD, University of Texas South-western Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-8885.
Current Author Addresses: Drs. Pak and Sakhaee, Ms. Adams-Huet, Mr. Peterson, and Mr. Poindexter: Center for Mineral Metabolism and Clinical Research, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-8885.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  E. J. MacLaughlin and C. L. Raehl ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults Am. J. Health Syst. Pharm., February 15, 2008; 65(4): 343 - 357. [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Reid, T. Cundy, A. B. Grey, A. Horne, J. Clearwater, R. Ames, B. J. Orr-Walker, F. Wu, M. C. Evans, G. D. Gamble, et al. Addition of Monofluorophosphate to Estrogen Therapy in Postmenopausal Osteoporosis: A Randomized Controlled Trial J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2446 - 2452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cunningham Pathogenesis and Prevention of Bone Loss in Patients Who Have Kidney Disease and Receive Long-Term Immunosuppression J. Am. Soc. Nephrol., January 1, 2007; 18(1): 223 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Hodsman, D. A. Hanley, M. P. Ettinger, M. A. Bolognese, J. Fox, A. J. Metcalfe, and R. Lindsay Efficacy and Safety of Human Parathyroid Hormone-(1-84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5212 - 5220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Brown and R. G. Josse Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada Can. Med. Assoc. J., March 18, 2003; 168(90060): SF1 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Grimes and R. A. Lobo Perspectives on the Women's Health Initiative Trial of Hormone Replacement Therapy Obstet. Gynecol., December 1, 2002; 100(6): 1344 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Brown and R. G. Josse 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada Can. Med. Assoc. J., November 12, 2002; 167(90100): s1 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Rubin, C. Y. C. Pak, B. Adams-Huet, H. K. Genant, J. Li, and D. S. Rao Sustained-Release Sodium Fluoride in the Treatment of the Elderly With Established Osteoporosis Arch Intern Med, October 22, 2001; 161(19): 2325 - 2333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Rosen and J. P. Bilezikian Anabolic Therapy for Osteoporosis J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 957 - 964. [Abstract] [Full Text]
|
|
|
|
|
|
E. S. Kurland, F. Cosman, D. J. McMahon, C. J. Rosen, R. Lindsay, and J. P. Bilezikian Parathyroid Hormone as a Therapy for Idiopathic Osteoporosis in Men: Effects on Bone Mineral Density and Bone Markers J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3069 - 3076. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Liang, S. Pun, and T. J. Wronski Bone Anabolic Effects of Basic Fibroblast Growth Factor in Ovariectomized Rats Endocrinology, December 1, 1999; 140(12): 5780 - 5788. [Abstract] [Full Text]
|
|
|
|
|
|
P. Alexandersen, B. J. Riis, and C. Christiansen Monofluorophosphate Combined with Hormone Replacement Therapy Induces a Synergistic Effect on Bone Mass by Dissociating Bone Formation and Resorption in Postmenopausal Women: A Randomized Study J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3013 - 3020. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. L. Greenspan A 73-Year-Old Woman With Osteoporosis JAMA, April 28, 1999; 281(16): 1531 - 1540. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Eastell Treatment of Postmenopausal Osteoporosis N. Engl. J. Med., March 12, 1998; 338(11): 736 - 746. [Full Text] [PDF]
|
|
|
|
 |
|
 W. F Lems, J. W G Jacobs, J. W J Bijlsma, G. J M van Veen, H. H M L Houben, H. C M Haanen, M. I Gerrits, and H. J M van Rijn Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis, June 1, 1997; 56(6): 357 - 363. [Abstract] [Full Text]
|
|
|
|
|
|
L. Holloway, L. Kohlmeier, K. Kent, and R. Marcus Skeletal Effects of Cyclic Recombinant Human Growth Hormone and Salmon Calcitonin in Osteopenic Postmenopausal Women J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1111 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Hodsman, L. J. Fraher, P. H. Watson, T. Ostbye, L. W. Stitt, J. D. Adachi, D. H. Taves, and D. Drost A Randomized Controlled Trial to Compare the Efficacy of Cyclical Parathyroid Hormone Versus Cyclical Parathyroid Hormone and Sequential Calcitonin to Improve Bone Mass in Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 620 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Managing osteoporosis DTB, June 1, 1996; 34(6): 45 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. LANE, E. H. RILEY, and P. Z. WIRGANOWICZ Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Osteoporosis: Diagnosis and Treatment*{{dagger}} J. Bone Joint Surg. Am., April 1, 1996; 78(4): 618 - 32. [Full Text]
|
|
|
|
 |
|
 SLOW-RELEASE FLUORIDE PREVENTS SPINAL FRACTURE Journal Watch (General), September 19, 1995; 1995(919): 6 - 6. [Full Text]
|
|
Article
